NeuroSense Regains Compliance with NASDAQ Minimum Bid Price Rule
NeuroSense Therapeutics (Nasdaq: NRSN) has regained compliance with Nasdaq's minimum bid price requirement. The company, which develops treatments for severe neurodegenerative diseases, received notice from Nasdaq confirming that it has met the Rule 5550(a)(2) criteria. To achieve this, NeuroSense's ordinary shares maintained a minimum closing bid price of $1.00 or more for at least 10 consecutive business days, accomplished on September 20, 2024.
CEO Alon Ben-Noon expressed satisfaction with this development, viewing it as an important step that reflects the company's commitment to advancing PrimeC. He also mentioned positive momentum following Phase 2b trial results and plans to initiate a Phase 3 trial in the US, along with ongoing discussions with potential partners.
NeuroSense Therapeutics (Nasdaq: NRSN) ha riottenuto la conformità con il requisito di prezzo minimo per le offerte di Nasdaq. L'azienda, che sviluppa trattamenti per gravi malattie neurodegenerative, ha ricevuto una comunicazione da Nasdaq che conferma di aver soddisfatto i criteri della Regola 5550(a)(2). Per raggiungere questo obiettivo, le azioni ordinarie di NeuroSense hanno mantenuto un prezzo di chiusura minimo di $1,00 o superiore per almeno 10 giorni lavorativi consecutivi, realizzato il 20 settembre 2024.
Il CEO Alon Ben-Noon ha espresso soddisfazione per questo sviluppo, considerandolo un passo importante che riflette l'impegno dell'azienda nel far progredire PrimeC. Ha anche menzionato uno slancio positivo a seguito dei risultati della sperimentazione di fase 2b e i piani di avviare una sperimentazione di fase 3 negli Stati Uniti, insieme a discussioni in corso con potenziali partner.
NeuroSense Therapeutics (Nasdaq: NRSN) ha recuperado la conformidad con el requisito de precio mínimo de oferta de Nasdaq. La compañía, que desarrolla tratamientos para enfermedades neurodegenerativas severas, recibió un aviso de Nasdaq confirmando que ha cumplido con los criterios de la Regla 5550(a)(2). Para lograr esto, las acciones ordinarias de NeuroSense mantuvieron un precio mínimo de cierre de $1.00 o más durante al menos 10 días hábiles consecutivos, alcanzado el 20 de septiembre de 2024.
El CEO Alon Ben-Noon expresó su satisfacción con este desarrollo, viéndolo como un paso importante que refleja el compromiso de la empresa con el avance de PrimeC. También mencionó un impulso positivo tras los resultados del ensayo de fase 2b y planes para iniciar un ensayo de fase 3 en EE. UU., junto con discusiones en curso con socios potenciales.
NeuroSense Therapeutics (Nasdaq: NRSN)가 Nasdaq의 최소 입찰 가격 요건을 회복했습니다. 중증 신경퇴행성 질환 치료제를 개발하는 이 회사는 Nasdaq으로부터 규칙 5550(a)(2) 기준을 충족했음을 통보받았습니다. 이를 달성하기 위해 NeuroSense의 보통주는 연속 10 영업일 이상 $1.00 이상의 최소 종가를 유지했습니다, 이는 2024년 9월 20일에 이루어졌습니다.
CEO Alon Ben-Noon은 이 발전에 대해 만족감을 표명하며, 이는 PrimeC의 발전에 대한 회사의 헌신을 반영하는 중요한 단계라고 언급하였습니다. 그는 또한 2b상 임상 시험 결과에 따른 긍정적인 모멘텀과 함께 미국에서 3상 임상 시험을 시작할 계획을 언급했으며, 잠재적인 파트너와의 지속적인 논의도 포함되었습니다.
NeuroSense Therapeutics (Nasdaq: NRSN) a rétabli sa conformité avec l'exigence de prix d'offre minimum de Nasdaq. L'entreprise, qui développe des traitements pour des maladies neurodégénératives graves, a reçu un avis de Nasdaq confirmant qu'elle a satisfait aux critères de la règle 5550(a)(2). Pour y parvenir, les actions ordinaires de NeuroSense ont maintenu un prix de clôture minimum de 1,00 $ ou plus pendant au moins 10 jours ouvrables consécutifs, réalisé le 20 septembre 2024.
Le PDG Alon Ben-Noon a exprimé sa satisfaction concernant ce développement, le considérant comme une étape importante qui reflète l'engagement de l'entreprise à faire avancer PrimeC. Il a également mentionné un élan positif suite aux résultats de l'essai de phase 2b et les projets de débuter un essai de phase 3 aux États-Unis, ainsi que des discussions en cours avec des partenaires potentiels.
NeuroSense Therapeutics (Nasdaq: NRSN) hat die Konformität mit dem Mindestangebotspreis von Nasdaq wiedererlangt. Das Unternehmen, das Behandlungen für schwere neurodegenerative Erkrankungen entwickelt, erhielt eine Mitteilung von Nasdaq, die bestätigt, dass es die Kriterien der Regel 5550(a)(2) erfüllt hat. Um dies zu erreichen, haben NeuroSense's Stammaktien einen minimale Schlusskurs von $1,00 oder mehr für mindestens 10 aufeinanderfolgende Geschäftstage gehalten, das am 20. September 2024 erreicht wurde.
CEO Alon Ben-Noon äußerte seine Zufriedenheit mit dieser Entwicklung und sieht sie als einen wichtigen Schritt, der das Engagement des Unternehmens zur Weiterentwicklung von PrimeC widerspiegelt. Er erwähnte auch positiven Schwung nach den Ergebnissen der Phase-2b-Studie und die Pläne, eine Phase-3-Studie in den USA zu initiieren, sowie laufende Gespräche mit potenziellen Partnern.
- Regained compliance with Nasdaq's minimum bid price requirement
- Positive momentum from Phase 2b trial results
- Plans to initiate Phase 3 trial in the US
- Ongoing discussions with potential partners
- None.
Insights
Regaining compliance with Nasdaq's minimum bid price requirement is a positive development for NeuroSense Therapeutics. This news removes the immediate risk of delisting, which could have severely impacted the company's access to capital and investor confidence. However, it's important to note that this compliance doesn't directly affect the company's fundamental business operations or financial performance.
The $1.00 minimum bid price is a critical threshold for maintaining Nasdaq listing and NeuroSense's ability to meet this requirement suggests a degree of market confidence in its prospects. The CEO's mention of positive momentum from Phase 2b trial results and plans for a Phase 3 trial indicates potential progress in their drug development pipeline, which is important for biotech companies.
Investors should focus on upcoming catalysts such as the initiation of the Phase 3 trial and any partnership announcements, as these factors are more likely to drive long-term value. While regaining compliance is reassuring, it doesn't guarantee future stock performance or clinical success. The company's market cap of
To regain compliance with the Rule, the Company's ordinary shares were required to maintain a minimum closing bid price of
NeuroSense's CEO, Alon Ben-Noon said, " We are pleased to have regained compliance with Nasdaq's minimum bid price requirement, an important step that reflects our commitment to advancing PrimeC. With the positive momentum following our Phase 2b trial results, we are looking forward to initiating the Phase 3 trial in the US and continuing our discussions with potential partners."
About NeuroSense
NeuroSense Therapeutics, Ltd. is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. NeuroSense believes that these diseases, which include amyotrophic lateral sclerosis (ALS), Alzheimer's disease and Parkinson's disease, among others, represent one of the most significant unmet medical needs of our time, with limited effective therapeutic options available for patients to date. Due to the complexity of neurodegenerative diseases and based on strong scientific research on a large panel of related biomarkers, NeuroSense's strategy is to develop combined therapies targeting multiple pathways associated with these diseases.
For additional information, we invite you to visit our website and follow us on LinkedIn, YouTube and X. Information that may be important to investors may be routinely posted on our website and these social media channels.
Forward-Looking Statements
This press release contains "forward-looking statements" that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as "anticipate," "believe," "contemplate," "could," "estimate," "expect," "intend," "seek," "may," "might," "plan," "potential," "predict," "project," "target," "aim," "should," "will" "would," or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on NeuroSense Therapeutics' current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict and include statements regarding initiating the Phase 3 trial for PrimeC in the US. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. The future events and trends may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward looking statements. These risks include unexpected R&D costs or operating expenses, a delay in the reporting of additional results from PARADIGM clinical trial or a delay in initiating the Phase 3 trial for PrimeC in the US, the timing of expected regulatory and business milestones, risks associated with meeting with the FDA to determine the best path forward following the results from PARADIGM clinical trial, including a delay in any such meeting; the potential for PrimeC to safely and effectively target ALS; preclinical and clinical data for PrimeC; the uncertainty regarding outcomes and the timing of current and future clinical trials; timing for reporting data; the development and commercial potential of any product candidates of NeuroSense; and other risks and uncertainties set forth in NeuroSense's filings with the Securities and Exchange Commission (SEC). You should not rely on these statements as representing our views in the future. More information about the risks and uncertainties affecting the Company is contained under the heading "Risk Factors" in the Annual Report on Form 20-F filed with the Securities and Exchange Commission on March 22, 2023. Forward-looking statements contained in this announcement are made as of this date, and NeuroSense undertakes no duty to update such information except as required under applicable law.
Logo: https://mma.prnewswire.com/media/1707291/NeuroSense_Therapeutics_Logo.jpg
View original content:https://www.prnewswire.com/news-releases/neurosense-regains-compliance-with-nasdaq-minimum-bid-price-rule-302257073.html
SOURCE NeuroSense
FAQ
What Nasdaq rule did NeuroSense Therapeutics (NRSN) regain compliance with?
When did NeuroSense Therapeutics (NRSN) achieve compliance with Nasdaq's minimum bid price rule?
What are NeuroSense Therapeutics' (NRSN) plans following regaining Nasdaq compliance?
Who is the CEO of NeuroSense Therapeutics (NRSN) mentioned in the press release?
